METUCHEN, N.J.--(BUSINESS WIRE)--Tevogen Bio, a clinical stage biotechnology company, announced the forthcoming clinical trial of TVGN-489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback